SCHEMBL207572

SCHEMBL207572

N#Cc1ccc(Nc2nc(-c3ccc(F)cc3)cs2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VCP P55072 2/20 0.76
ALOX5 P09917 3/20 0.69
SMN1; SMN2 Q16637 7/20 0.68
MAPT P10636 6/20 0.68
RAB9A P51151 4/20 0.68
NPC1 O15118 3/20 0.68
TDP1 Q9NUW8 2/20 0.68
NPY5R Q15761 1/20 0.68
POLB P06746 1/20 0.68
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
MAPK1 P28482 2/20 0.62
CFTR P13569 2/20 0.59
ALDH1A1 P00352 2/20 0.57
LMNA P02545 2/20 0.57
HPGD P15428 2/20 0.57
GAA P10253 2/20 0.57
USP2 O75604 1/20 0.57
AMY1A P0DUB6 1/20 0.57
THRB P10828 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926815 0.89 ALOX5 (0.85) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL206229 0.86 VCP (0.76) VCPALOX5SMN1; SMN2MAPTNPC1
SCHEMBL7109033 0.86 VCP (0.76) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL7111888 0.86 VCP (0.76) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL1821422 0.86 VCP (0.76) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL1892520 0.86 VCP (0.76) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL31126469 0.86 ALOX5 (0.71) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL208940 0.85 NPY5R (0.66) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL1821487 0.83 VCP (0.71) VCPALOX5SMN1; SMN2MAPTRAB9A
SCHEMBL205404 0.82 VCP (0.65) VCPALOX5SMN1; SMN2MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 VCP 1270/4885ALOX5 3410/4885SMN1; SMN2 3252/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 VCP 1270/4885ALOX5 3410/4885SMN1; SMN2 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.